(Q39340772)

English

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer

scientific article published on 23 January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

based on heuristic

inferred from title

samarium (153sm) lexidronam

1 reference

based on heuristic

inferred from title

author name string

Sergio Ricci

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Giuseppe Boni

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ilaria Pastina

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Dario Genovesi

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Claudia Cianci

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Serena Chiacchio

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Cinzia Orlandini

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Mariano Grosso

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Abedallatif Alsharif

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Aldo Chioni

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Samantha Di Donato

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Francesco Francesca

12

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Cesare Selli

13

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Domenico Rubello

14

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Giuliano Mariani

15

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

23 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1023-1030

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Samarium for osteoblastic bone metastases and osteosarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radionuclide therapy in oncology: repeated administrations of high dose rate radiopharmaceuticals

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of metastatic bone pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2003.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiopharmaceutical therapy for palliation of bone pain from osseous metastases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carcinoma of the prostate: metastases, therapy and survival; a statistical analysis of five hundred cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone-seeking radionuclides for therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Critical evaluation of hormonal therapy for carcinoma of the prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting prostate cancer bone metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/17242920

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-006-0343-8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

release_dvaecfvtfnbznh5gcyz5zbeou4

1 reference

https://api.fatcat.wiki/v0/release/dvaecfvtfnbznh5gcyz5zbeou4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39340772&oldid=2202792884"